誉衡药业(002437) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥681,168,970.96, a decrease of 12.02% compared to ¥774,211,987.48 in the same period last year[4] - Net profit attributable to shareholders reached ¥20,058,598.74, representing a significant increase of 1,909.35% from ¥998,263.43 year-on-year[4] - Basic and diluted earnings per share were both ¥0.0091, an increase of 1,720.00% compared to ¥0.0005 in the same period last year[4] - The total operating revenue for the current period is ¥681,168,970.96, a decrease of 11.99% compared to ¥774,211,987.48 in the previous period[20] - The net profit for the current period is ¥21,870,444.70, significantly higher than ¥3,046,070.09 in the previous period, marking a growth of 619.06%[21] - The total comprehensive income for the current period is ¥21,156,409.21, compared to ¥2,822,278.80 in the previous period, showing a substantial increase[21] Cash Flow - The net cash flow from operating activities was ¥83,699,367.15, up 47.30% from ¥56,821,196.52 in the previous year[4] - The net cash flow from operating activities was ¥83,699,367.15, an increase from ¥56,821,196.52 in the previous period, indicating a positive trend in operational cash generation[24] - The net cash flow from investing activities was ¥25,147,232.08, a turnaround from a negative cash flow of ¥117,006,134.10 in the previous year[9] - The net cash flow from financing activities was -¥101,258,939.96, compared to -¥27,724,573.13 in the previous period, showing increased cash outflows related to financing[25] - The total cash inflow from investment activities was ¥57,198,472.28, significantly lower than ¥314,461,007.58 in the previous period, reflecting a decrease in investment returns[24] - The net increase in cash and cash equivalents was ¥6,815,714.09, contrasting with a decrease of ¥88,440,630.07 in the previous period, suggesting improved liquidity management[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,948,401,721.10, a decrease of 3.09% from ¥4,074,185,955.01 at the end of the previous year[4] - The total liabilities amount to ¥2,235,154,094.49, a decrease from ¥2,370,644,737.61 in the previous period[18] - The total current assets are reported at 1,738,338,700.12 RMB, a decrease from 1,816,197,553.88 RMB, indicating a decline of about 4.3%[16] - The total non-current assets amount to 2,210,063,020.98 RMB, down from 2,257,988,401.13 RMB, representing a decrease of approximately 2.1%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 93,421[11] - Harbin Yuheng Group Co., Ltd. holds 32.13% of shares, totaling 706,248,522 shares, which are frozen[11] - The top ten shareholders include YU HENG INTERNATIONAL INVESTMENTS CORPORATION with 2.58% and ORIENTAL KEYSTONE INVESTMENT LIMITED with 1.95%[11][12] - The company has no controlling shareholder or actual controller as of the report date, following the bankruptcy of Harbin Yuheng Group[13] - The company’s stock held by Harbin Yuheng Group has been completely auctioned and transferred, with no remaining shares held by the group[13] Operational Efficiency - The total operating costs for the current period are ¥636,373,987.48, down 13.27% from ¥733,867,370.83 in the previous period[20] - Research and development expenses for the current period are ¥13,997,253.96, down from ¥19,378,770.25 in the previous period, indicating a reduction of 27.56%[20] - Cash paid for purchasing goods and services was ¥98,639,590.05, compared to ¥161,161,410.50 in the previous period, reflecting a decrease in operational expenditures[24] - Cash paid for employee compensation was ¥115,102,392.56, down from ¥160,976,169.26, indicating cost control measures[24] Investment Performance - The company reported an investment loss of ¥20,774,804.75, compared to a loss of ¥10,283,242.28 in the previous period, representing an increase in losses[20] - Investment income showed a significant decline of 102.03%, with losses from equity method investments increasing[9] - The company reported cash received from investment recoveries of ¥56,383,625.67, a significant drop from ¥300,150,000.00 in the previous period[24] Legal Matters - The company has ongoing litigation related to a contract dispute, with a total of 1,524.40 million RMB received and 140.09 million RMB still owed[14] Management and Control - The company’s management team remains stable, and its independent operational capability is not affected by the change in control[13]